Khanh,
I'm coming to Austin next week for the Young Plasma Exchange protocol. That's the reason for the visit — I take my own longevity seriously, and your clinical work is the best fit I've found for it.
While I was preparing for the visit, I started looking at your business the way I'd look at one of my own portfolio companies. I couldn't help it. This document is what I saw.
When we first met, you told me something I haven't stopped thinking about. You said that whenever you start with a patient, you start with the goal. What do they want? How long do they want to live? What does the next twenty years need to look like?
In my space, it's exactly the same.
So that's where I started with you. Your goal — the one you actually named — is five to seven practices. Not a hundred. Not a worldwide network in three years. Five to seven thoughtful, intentional, replicable practices that prove the ART model travels.
That clarity changes everything.
There's something else I haven't stopped thinking about either. At the end of our first conversation, you looked at me and said, "I will WOW you." And I said, "And I will WOW you." Consider this document the first half of that promise.
I've spent the last several days going deep on your business. Reading every page of your site. Listening to both Greenfield episodes. Looking at what Cenegenics did, what Next Health is doing, what Sollis built. Mapping the regulatory terrain in Texas and the adjacent states where you could realistically go next. Studying the failure case studies — Ambrosia, QC Kinetix's plateau, the chains that couldn't translate one great clinic into many.
Here's what I see.
Austin Regenerative Therapy is sitting on a category that doesn't yet exist — physician-led, clinically rigorous, ultra-premium regenerative medicine. Your refugee-to-pioneer narrative, the Critical Care credentialing depth, the Greenfield endorsement, the Young Plasma™ co-investigator status — these are not assets that can be replicated. They are the prerequisites of a category-defining brand.
What you don't yet have is the architecture to scale them without diluting them. That's what this document is about — and that's what I do.
Read it the way you'd read a clinical workup: diagnosis first, then the protocol. Section by section, you'll see exactly what I see — where ART stands today, what the market is doing, where your real moat is, and what the next eighteen months must look like to credibly open Practice Two, then Three, then Five. You'll also see the framework I've built specifically for physician-entrepreneurs in your space: The Regenerative Practice Method™. It is the spine of everything that follows.
The last two sections — Why Me and How We Work Together — are for context, not for closing. Read them when you're done with the diagnosis. We can talk through any of it in person.
Either way, this was written for you. I'll see you in Austin.
Your goal is five to seven practices. The work of this document is to make those five to seven practices inevitable — and to build them in a way that earns the right to whatever comes after, on your terms.
By 2030, ART is a five-to-seven location regional network anchored in Texas and the immediately adjacent CPOM-favorable Sunbelt states, with a national telehealth and concierge layer reaching patients well beyond the physical footprint.
By that point, ART is also a platform — not just a practice. The intellectual property is locked. A training and certification program is producing partner physicians who carry the ART standard. The Intelligent Acquisition Engine is generating qualified patient flow at every location without the founder having to be the brand at every appearance. Capital partners are at the table.
And if you choose to expand further — to ten, to twenty-five, to one hundred — the infrastructure to do it is already built.
Whether you stop at seven or scale to one hundred is your decision. The job of this plan is to make sure that decision is yours to make.
Lock the IP. Build the telehealth and CRM layer. Hire the COO. Open Practice Two — likely Dallas, Houston, or Austin-adjacent.
Three to five flagships across Texas and adjacent CPOM-favorable markets — selected against criteria, not assumption. National brand recognition. Growth equity if and when economics warrant.
Five to seven thriving practices. A complete platform — brand, MSO, training program, AI engine, capital structure — ready to support whatever you choose next.
A four-pillar framework for scaling a physician-led specialty practice from one clinic into a category-defining brand — without surrendering the clinical integrity, founder voice, or patient experience that built it.
The hardest sentence in healthcare is this one: a great practice rarely scales, and a scaled practice rarely stays great. Most boutique medical brands collapse under their own growth — voice dilutes, quality slips, the founder becomes a bottleneck, the patient experience that built the original location becomes impossible to replicate at the next one.
The few brands that succeed at scale do so because they architected for it before they tried it.
The Regenerative Practice Method™ is that architecture. Refined across thirty-four years of brand strategy and seven seven-figure businesses, it was built specifically for physician-entrepreneurs in regenerative, functional, and longevity medicine who intend to build something category-defining — not just open more rooms.
It rests on four pillars. They are sequenced intentionally. None can be skipped. Each compounds the next.
The brand IP, voice, narrative, and clinical protocols that define what makes this practice unrepeatable. Trademark portfolio. Signature protocols. Founder narrative architecture. Voice systems that allow partner physicians to carry the Defy Time · Age Boldly · Live Fully promise without diluting it.
The legal, operational, and clinical infrastructure that makes location two look, feel, and perform like location one. MSO + Professional Corporation structure, CPOM-compliant in all 50 states. Physician partnership model and economics. Operations playbook. Training and certification program. Quality assurance cadence.
The AI-augmented patient acquisition, conversion, and retention infrastructure that converts media moments into a national patient pipeline. AI content engine that scales the founder's voice. AI lead qualification. Personalized longevity scorecards. Multi-channel demand generation. Telehealth onboarding. Patient retention systems.
The financing, partnership, and exit-readiness sequence that funds the build and creates the realization event. Bootstrap and revenue-reinvest through locations one to five. Growth equity round anchored on platform valuation. Fee-funded expansion. Exit positioning for strategic acquisition or IPO at year five to seven.
This is not a sidebar. The Method assumes AI as infrastructure, not feature. AI-augmented brand voice systems (Pillar I). AI-driven compliance and protocol consistency across locations (Pillar II). The Intelligent Acquisition Engine itself (Pillar III). AI-powered dashboards, valuation modeling, and exit-readiness diagnostics (Pillar IV). The next generation of category-defining boutique medical brands will be the ones who treat AI as a clinical-grade infrastructure decision — not a marketing tactic.
Thirty-two years of medicine. Board Certified in Internal Medicine and Anti-Aging Medicine (A4M). Critical Care fellowship trained at Rush. Active licenses in Texas and California. Eight years as Internal Medicine Hospitalist at St. David's HealthCare before pivoting full-time to regenerative practice in 2018.
Unlike most functional and wellness practitioners, Dr. Nguyen brings a board-certified internist and Critical Care background to procedures that competitors routinely perform with substantially lesser training. This is a credentialing moat.
Her breakout media moment is a two-episode feature on Ben Greenfield's Boundless Life Podcast — May 2025 and January 2026. Greenfield spent three days at the clinic and described it as one of his most transformative experiences. The kind of validation that money cannot easily buy.
A high-acuity, cash-pay specialty practice organized around three patient-facing pillars she has already built into her brand:
| Defy Time | Age Boldly | Live Fully |
|---|---|---|
| VSEL Stem Cell Therapy Young Plasma™ Exchange Therapeutic Plasma Exchange PRP Injections · P-Shot · O-Shot NEO-7 Peptide Protocols BioTe Hormone Pellets |
Regen Facelift NOUVADerm Skin Restoration Regenerative Hair Restoration IV Vitamins & NAD+ Early Detection Panels PNOE VO2 Max Testing |
Concierge Membership Programs VO2 Max, Lean Mass, HRV Tracking Nutrition · Sleep · Stress Coaching Community & Whole-Person Care Biological Age Testing Personalized Optimization |
Pricing & positioning: luxury / ultra-premium, deliberately opaque. No public pricing page — all pricing is consultation-dependent. Base treatment packages estimated in the $1,500–$10,000+ range per protocol. Annual revenue (directional): $1.5M – $3.5M based on team size, premium pricing tier, and comparable single-location regenerative clinic economics.
Age 40–65, household income $250K+, net worth $1M+. C-suite, founders, physicians, pro athletes, real estate, hedge funds. Reads Outlive. Follows Greenfield and Huberman. Perceives health as ROI, not luxury.
This patient is not bought through a sales sequence. They are invited in through a brand that earns their trust before they ever pick up the phone. Trigger events: fatigue diagnosis, hormonal shift, injury, biomarker scare, peer or podcast referral. Decision drivers: physician credentials, clinical evidence depth, protocol sophistication, peer word-of-mouth, brand exclusivity.
The Corporate Practice of Medicine doctrine prohibits non-physician entities from employing physicians in approximately thirty states. The MSO + Professional Corporation model is the industry-standard solution and is non-negotiable for ART's scale path.
Most favorable Phase 1 markets: Texas (current), Alabama, Arizona, Nevada, Florida, Tennessee — Sunbelt, HNWI-dense, CPOM-favorable.
Strictest CPOM requirements: California, New York, Colorado, Illinois — must be structured with state-specific legal counsel before entry. California SB 351 (2026) tightened the MSO-PC firewall further. ART's expansion legal team must be CPOM-versed by state.
The combination of VSEL therapy, Young Plasma™ Exchange, and the Greenfield endorsement creates a service-and-credibility differentiation that no other Austin clinic currently replicates. CHARM and Regenerative Medicine Austin compete on orthopedic pain — a different patient avatar. Dr. Harper and Austin Precision Medicine are the closest competitors for the longevity-optimization patient, but neither has ART's high-acuity service depth or equivalent media profile.
| QC Kinetix 2022–2024 Plateau | QC Kinetix scaled rapidly to 100+ franchise locations across the U.S. — but franchise economics in pain-relief protocols are structurally thin, raising questions about unit economics and brand consistency at scale. Lesson: do not franchise before three to five consistently profitable corporate locations validate the unit economics. |
| Ambrosia & Young Plasma Freeze | FDA warning (2019) effectively halted Ambrosia's commercial operations. ART's positioning as co-investigator on a clinical study — rather than purely commercial operator — is a meaningful regulatory shield. Lesson: ongoing IRB vigilance and conservative claims are non-negotiable. |
| Cenegenics Velocity | The only physician-led ultra-premium longevity brand to scale meaningfully — yet it took 25 years to reach ~20 locations. Lesson: ART must engineer a model that combines Cenegenics' clinical depth with Next Health's franchise velocity. |
Every content piece is anchored to the founder's identity. This humanizes the brand and is part of why it works — but it creates brand continuity risk when a partner physician operates a new location. A second author voice (educational, protocol-anchored, non-personal) must be developed in parallel.
The business operates under both Austin Regenerative Medicine (domain) and Austin Regenerative Therapy (primary brand name, social handles, team page). At single-clinic scale this is forgivable. At fifty locations it becomes a brand-equity tax. Unification must happen before partnership conversations begin.
Each of these represents an opportunity within Pillar III of the Method. The specific sequencing, build approach, and execution detail lives inside the engagement.
| Asset | Status | Pillar |
|---|---|---|
| Owned audio property | Absent | Pillar I · Practice Identity |
| Founder-narrative book / signature methodology | Absent | Pillar I · Practice Identity |
| Owned long-form video channel | Absent | Pillar III · Engine |
| Email / SMS automation | Newsletter only | Pillar III · Engine |
| PubMed-indexed publication | Absent | Pillar I · Practice Identity |
| Trademarked protocol portfolio | YPE only | Pillar I · Practice Identity |
| Paid media acquisition engine | Absent | Pillar III · Engine |
| Indexed conference circuit | RAADfest only | Pillar I · Practice Identity |
| Ambassador / physician referral system | Ad-hoc | Pillar III · Engine |
| Model | Recommendation | Why |
|---|---|---|
| MSO-Affiliated Physician Partnership | Primary | CPOM-compliant in 30 states. Aligns physician incentives. Capital-light per location. Leverages local market knowledge. |
| Corporate-Owned Flagships | Secondary | Austin + 2–3 flagship markets only. Full brand control, training centers, highest QC. Capital-intensive. |
| Franchise | Defer | Only after 10+ locations proven. QC Kinetix cautionary tale on brand dilution. |
| Pure Licensing | Reject | Minimal brand control — incompatible with a clinical-quality brand. |
Phase 1 market selection runs against five criteria: CPOM-favorable regulatory environment, HNWI density above $250K household income, biohacker-cultural penetration, proximity sufficient for direct clinical oversight, and adjacency to existing brand awareness or referral networks. The specific market sequence, market entry order, and partnership economics live inside the engagement.
Texas + adjacent CPOM-favorable states. Direct ownership through MSO entity. No JV partnerships until model proven.
Largest HNWI concentrations and national digital reach. Growth equity round or fee-funded expansion.
JV with local healthcare operators. International JVs deferred until U.S. platform proven.
Six categories of strategic moves that compound. The naming, sequencing, partnerships, and execution detail for each lever live inside the engagement.
| Owned audio property | Founder-led long-form audio at scale. Captures the audience overlap Greenfield has already proven. |
| Founder-narrative book | Memoir-meets-medicine. The refugee-to-pioneer arc as the highest-ROI earned-media multiplier. |
| Trademark portfolio expansion | Federal registration of signature protocols. MSO-owned IP that protects partnership economics. |
| Conference circuit strategy | Tier-one longevity and biohacking conferences. Earned media, speaking fees, physician-recruitment pipeline. |
| Ambassador architecture | Visible health-journey partners. The fastest credibility elevator in the male HNWI demographic. |
| Physician training flywheel | Formalized certification program. Trained physicians become natural network affiliates. |
| Proven unit economics at 3+ locations — replication, not just the flagship |
| Technology moat — centralized EHR/CRM, digital acquisition engine, telehealth layer |
| Membership / recurring revenue — 20%+ from predictable monthly memberships |
| Proprietary IP and trademarked protocols |
| Physician independence from founder — brand must survive Dr. Nguyen's reduced clinical role |
| Clean regulatory history — no FDA warning letters, no TMB actions, conservative claims |
| Management team depth — physician-founder alone is insufficient; COO, CMO, CFO required |
| Risk | Severity | Mitigation |
|---|---|---|
| FDA enforcement on YPE / VSEL / exosomes | Critical | Maintain clinical trial affiliation · conservative marketing · legal counsel on standby · quarterly enforcement-trend reviews |
| Peptide compounding restrictions eliminate core service | High | Diversify menu off Category 2 peptides · transition to Category 1 + HRT + NAD+ primary |
| Clinical adverse event at affiliate location | Critical | Rigorous physician vetting · standardized protocols · malpractice insurance requirements · quality audit cadence |
| Brand dilution through partnership scale | High | MSO model preferred over franchise · physician partnership criteria gated on training and protocol adherence |
| Founder dependency — current state | High | Develop second-tier physician talent · podcast and book create founder-independent brand IP · COO decouples ops |
| Competitor replication of YPE / VSEL positioning | Medium | Speed of expansion + brand equity is the moat · trademark filings protect protocol naming |
| PE hesitation on unapproved therapies | Medium | Frame as physician-led functional medicine network · emphasize HRT / longevity as primary positioning |
| Key staff departure | Medium | Succession planning · competitive compensation · equity participation in MSO entity |
It takes decades of brand-strategy reps — across multiple industries, at multiple stages, with founders at every level of sophistication — to learn which decisions compound and which ones quietly kill the brand five years later. There are shortcuts to running ads. There are no shortcuts to that pattern recognition.
I have those reps.
I have watched founder-led brands collapse trying to scale, and I have watched founder-led brands compound trying to scale. The difference is not the founder. It is the architecture they put in place before the second location opens. I know what that architecture looks like because I have built it.
The patient you serve is not bought through a sales sequence. They are invited in through a brand that earns their trust before they ever pick up the phone. I have spent thirty-four years in markets where trust is the only currency that matters.
Most operators talk about AI. Some bolt it onto a workflow. I architect it as infrastructure — the way you architect HVAC into a building, not the way you bolt on a thermostat. The ART of 2030 will run on AI infrastructure designed today.
I work fast. I write directly. I don't waste your time with corporate language or false certainty. When something is a judgment call, I will say so. When the right answer is "we don't know yet — here is how we find out," I will say that too. The work is too important to hide behind a deck.
You will always know what I think. You will always know why. And you will always have the final call.
We've already talked about this — you've told me you want my help scaling ART. The question isn't whether we work together. The question is what that looks like. So this section isn't a cold proposal. It's the written shape of a conversation we've already started, so you can read it carefully, share it with anyone you trust, and think clearly about whether the structure of it actually works for you.
Before I describe that structure: this is what the partnership would look like if we both decided to do this. We may not. That decision is for after the three days, not before. I'm describing the shape of it so you can think about whether it's something you'd want — not because I assume the answer is yes.
I'm going to be honest with you about why this section looks different than what most consultants would write.
You don't need a plan you can't execute. The architecture in this document — the AI Operating Layer, the codified brand voice, the partner-physician certification system, the capital readiness materials — is not something a strategic plan alone gets you. It has to be built. By someone whose full-time job is building it. That's not a criticism of your team — it's just the honest scope of the work.
So if we did this, the only honest engagement structure would be one where I lead the building, alongside you. For the next eighteen to twenty-four months. Reporting to you as principal. Executing across all four pillars of the Method.
Cash retainer, build budget, equity percentage, and milestone triggers are conversations for when I'm there in person. Numbers depend on what we both agree the scope actually is, where you want to start, and what you're willing to commit to.
Bring your hardest questions about the structure. I'll bring mine.
One thing worth saying clearly: everything I build for ART belongs to ART. Your brand voice, your AI infrastructure, your patient acquisition systems, your operational playbooks — all yours. The Method is mine; the work is yours.
I'm not a consultant who needs your business. I'm not an agency looking for another logo on my client roster. I'm not a fractional CMO trying to land a retainer.
I run AI products for blockchain ventures doing eight figures. I co-own an AI productivity company. I sit on the Rally Community Council. I've built and exited seven figure businesses, plural. I'm a Forbes Top 10 Digital Marketing Influencer with thirty-four years of marketing experience, fluent in AI, fluent in brand, fluent in capital. My time is the constraint — not my pipeline.
Which means: if I commit to this work, it's because the business is worth my time. And if we work together, it's because we both decided this matters more than the other things competing for those hours.